Olaparib 300mg tablets

DRUG3 trials

Conditions

Advanced Ovarian CancerBRCA MutatedBRCA MutationComplete ResponseFIGO Stage III-IVFirst Line Platinum ChemotherapyFollowing Complete or Partial Response to Platinum Based ChemotherapyNewly Diagnosed

Phase 3

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

Active, not recruitingNCT01844986

AstraZenecaAdvanced Ovarian Cancer, BRCA Mutation, Complete Response +4

Start: 2013-08-26End: 2028-08-29Updated: 2025-12-10

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Active, not recruitingNCT01874353

AstraZenecaBRCA Mutated, Following Complete or Partial Response to Platinum Based Chemotherapy, Platinum Sensitive +1

Start: 2013-09-03End: 2026-12-31Updated: 2026-07-29

Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

CompletedNCT03534453

AstraZenecaFollowing Complete or Partial Response to Platinum Based Chemotherapy, Platinum Sensitive, Relapsed Ovarian Cancer

Start: 2018-05-29End: 2025-01-27Updated: 2025-07-10

2024-12-185 citations

Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer.

2024-11-121 citations

Overall survival (OS) in patients with platinum-sensitive relapsed ovarian cancer (PSROC) treated with olaparib maintenance monotherapy: Update from the L-MOCA trial.

Journal of Clinical Oncology2024-06-011 citations

Exploratory biomarker analysis in the phase III L-MOCA study of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer.

2024-05-165 citations

#512 Real-World utilisation and clinical outcomes of patients with BRCA-mutated advanced ovarian cancer treated with olaparib in the first-line maintenance setting: 2-year clinical outcomes of the pan-European OVAL-1 study

2023-09-011 citations

Multidisciplinary considerations in the maintenance treatment of poly(ADP‐ribose) polymerase inhibitors for homologous recombination‐proficient, advanced‐stage epithelial ovarian cancer

CA A Cancer Journal for Clinicians2022-11-1110 citations

Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial

Journal of Clinical Oncology2022-09-09425 citations

Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.

2022-06-27121 citations

Maintenance olaparib in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by somatic (s) or germline (g) BRCA and other homologous recombination repair (HRR) gene mutation status: Overall survival (OS) results from the ORZORA study.

Journal of Clinical Oncology2022-06-015 citations

Real-world effectiveness of first-line maintenance olaparib in women with <i>BRCA-</i>mutated advanced ovarian cancer: U.S. retrospective cohort study.

Journal of Clinical Oncology2022-06-011 citations

Exploratory hrd and PD-L1 analysis of l-MOCA study: Olaparib maintenance monotherapy in Asian patients with platinum-sensitive relapsed ovarian cancer.

Journal of Clinical Oncology2022-06-01

Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA)

Clinical Cancer Research2022-02-0144 citations

Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trial.

2021-11-0410 citations

Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.

2021-10-26268 citations

Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial.

2021-08-0230 citations

Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION primary analysis.

Journal of Clinical Oncology2021-05-206 citations

L-MOCA: An open-label study of olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer.

Journal of Clinical Oncology2021-05-202 citations

Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial.

2021-04-1338 citations

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.

2021-03-18306 citations

392 Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: subgroup analysis by risk in the phase III solo1 study

Ovarian cancer2020-12-018 citations

29 more papers not shown

Olaparib 300mg tablets

Sponsors

Conditions

Phase 3

Related Papers